CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $835,312 | -21.3% | 18,403 | -2.6% | 0.01% | -16.7% |
| Q2 2023 | $1,061,046 | +25.8% | 18,900 | +1.3% | 0.01% | +20.0% |
| Q1 2023 | $843,585 | +0.9% | 18,651 | -12.6% | 0.01% | -37.5% |
| Q4 2022 | $836,001 | -31.5% | 21,332 | +14.1% | 0.01% | -42.9% |
| Q3 2022 | $1,221,000 | -4.3% | 18,689 | -7.7% | 0.01% | 0.0% |
| Q2 2022 | $1,276,000 | -6.8% | 20,255 | -5.2% | 0.01% | +16.7% |
| Q1 2022 | $1,369,000 | -34.4% | 21,360 | -19.3% | 0.01% | -29.4% |
| Q4 2021 | $2,088,000 | -14.5% | 26,479 | +21.4% | 0.02% | -22.7% |
| Q3 2021 | $2,442,000 | -13.1% | 21,815 | +16.8% | 0.02% | -8.3% |
| Q2 2021 | $2,810,000 | – | 18,671 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |